Victoria A. Muggia
<p style=" font-size: 12.0pt; margin-left: 0in; margin-right: 0in; font-family: 'Times New Roman';">Infections in solid organ and bone marrow transplant recipients</p>
<p style=" font-size: 12.0pt; margin-left: 0in; margin-right: 0in; font-family: 'Times New Roman';">Infections in solid organ and bone marrow transplant recipients</p>
<p><span style="font-family: 'Times New Roman'; font-size: 12.0pt;">Infectious complications of HIV</span></p>
<p><span style="font-family: 'Times New Roman'; font-size: 12.0pt;">Infectious complications of solid organ transplantation</span></p>
<p><span style="font-family: 'Times New Roman'; font-size: 12.0pt;">Infectious complicatons of hematologic oncology</span></p>
<p>Dr. Meyerowitz is a clinician educator with interests in HIV and other viral diseases, complex infectious diseases, and sexually transmitted infections. His goal is to provide excellent and compassionate care that meets the needs of all of his patients.</p>
<p>Dr. Meyerowitz received his MD from the Perelman School of Medicine at the University of Pennsylvania. He completed his internship and residency at the University of Washington in Seattle, where he was a member of the HIV Medicine Pathway, training in the Madison Clinic, a dedicated HIV clinic. He then completed his fellowship in infectious diseases in the HIV Clinician Educator track at Massachusetts General Hospital in Boston. He joined the infectious diseases division at Albert Einstein Montefiore Medical Center in July 2020, spending time in outpatient clinics at the Oval Center and the Center for Positive Living, as well as time on the inpatient consultation services at the Moses Campus of Montefiore Medical Center.</p>
<p>Clinical interests:</p>
<p>- HIV prevention and treatment, including treatment of opportunistic infections</p>
<p>- Gender affirming care</p>
<p>- Care for people who inject drugs</p>
<p>- SARS-CoV-2/COVID-19 transmission, pathogenesis, treatment, and outcomes</p>
<p>- Care for people with mpox virus infection</p>
<p>- Mycobacterial infections</p>
<p>- Chronic viral infections, including viral hepatitis and HTLV-1</p>
<p>- Treatment of highly resistant bacterial infections</p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Coe J, Puius Y, Jain H, <strong>Meyerowitz EA</strong>. Cervical lymphadenitis from Mycobacterium avium complex. BMJ Case Rep. 2024 Mar 15;17(3):e256726. doi: 10.1136/bcr-2023-256726. PMID: 38490710; PMCID: PMC10946343.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Guha Roy S, Neilan AM, Ross DS, Mahowald GK. Case 5-2024: A 36-Year-Old Man with Fevers. N Engl J Med. 2024 Feb 15;390(7):653-660. doi: 10.1056/NEJMcpc2312724. PMID: 38354145.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Scott J, Richterman A, Male V, Cevik M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol. 2023 Dec 19. doi: 10.1038/s41579-023-01001-1. Epub ahead of print. PMID: 38114838.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Mullis CE, Marlow KA, Maity A, Fazzari M, Zingman BS, Keller MJ, <strong>Meyerowitz EA</strong>. Clinical presentations and treatment outcomes of Mycoplasma genitalium infections at a large New York City healthcare system. Sex Transm Dis. 2023 Dec 13. doi: 10.1097/OLQ.0000000000001911. Epub ahead of print. PMID: 38100794.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Li Y. Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses. Clin Infect Dis. 2023 Nov 9:ciad685. doi: 10.1093/cid/ciad685. Epub ahead of print. PMID: 37949817.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Irshad U, Bishop D, Mullis C, Toro J, Zingman BS, <strong>Meyerowitz EA</strong>. Implementation of an Mpox Vaccination Program at a Large Sexual Health Clinic in the Bronx-Lessons in Vaccine Equity. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad544. doi: 10.1093/ofid/ofad544. PMID: 38023548; PMCID: PMC10651189.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Mukerji SS, Kyle Harrold G, Erdil RM, Chen ST, Rudmann EA, Tsibris A, Venna N, Robbins GK. Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series. Clin Infect Dis. 2023 Sep 18;77(6):851-856. doi: 10.1093/cid/ciad281. PMID: 37157862; PMCID: PMC10681635.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Thornhill JP, Palich R, Ghosn J, Walmsley S, Moschese D, Cortes CP, Galliez RM, Garlin AB, Nozza S, Mitja O, Radix AE, Blanco JL, Crabtree-Ramirez B, Thompson M, Wiese L, Schulbin H, Levcovich A, Falcone M, Lucchini A, Sendagorta E, Treutiger CJ, Byrne R, Coyne K, <strong>Meyerowitz EA</strong>, Grahn AM, Hansen AE, Pourcher V, DellaPiazza M, Lee R, Stoeckle M, Hazra A, Apea V, Rubenstein E, Jones J, Wilkin A, Ganesan A, Henao-Martínez AF, Chow EJ, Titanji BK, Zucker JE, Ogoina D, Orkin CM; Share-Net writing group. Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series. Lancet. 2022 Dec 3;400(10367):1953-1965. doi: 10.1016/S0140-6736(22)02187-0. Epub 2022 Nov 17. PMID: 36403584; PMCID: PMC9671743.</span></span></span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Meyerowitz EA</strong>, Gendlina I, Desai VJ, Grossberg R, Nair SR, Pujar B, Riska PF, Root HB, Toro J, Torres JA, Pirofski LA, Zingman BS. Anorectal Testing for Mpox Virus Infection in Men Who Have Sex With Men With and Without Proctitis. Clin Infect Dis. 2023 Mar 4;76(5):934-937. doi: 10.1093/cid/ciac825. PMID: 36227656.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Bernardo RM, Collins-Ogle MD, Czeresnia JM, Matos CM, Mullis C, Root HB, Torres-Isasiga JA, Tsai H, Zingman BS. Navigating Human Immunodeficiency Virus Screening Recommendations for People on Pre-Exposure Prophylaxis and the Need to Update Testing Algorithms. Open Forum Infect Dis. 2022 Apr 15;9(7):ofac191. doi: 10.1093/ofid/ofac191. PMID: 35794936; PMCID: PMC9251658.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Richterman A. SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. Infect Dis Clin North Am. 2022 Jun;36(2):267-293. doi: 10.1016/j.idc.2022.01.007. Epub 2022 Feb 1. PMID: 35636900; PMCID: PMC8806027.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, Ciapponi A, Cevik M, Hauser A, Alam MI, Meili K, <strong>Meyerowitz EA</strong>, Prajapati N, Qiu X, Richterman A, Robles-Rodriguez WG, Thapa S, Zhelyazkov I, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLoS Med. 2022 May 26;19(5):e1003987. doi: 10.1371/journal.pmed.1003987. PMID: 35617363; PMCID: PMC9135333.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Richterman A, <strong>Meyerowitz EA</strong>, Cevik M. Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination. Open Forum Infect Dis. 2021 May 19;9(2):ofab259. doi: 10.1093/ofid/ofab259. PMID: 35071679; PMCID: PMC8194790.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Bernardo RM, <strong>Meyerowitz EA</strong>. A 35-Year-Old Man With An Itch. Clin Infect Dis. 2021 Nov 2;73(9):1733-1734. doi: 10.1093/cid/ciab117. PMID: 34732015.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;">Hock H, Kelly HR, <strong>Meyerowitz EA</strong>, Frigault MJ, Massoth LR. Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal Petechiae. N Engl J Med. 2021 Oct 14;385(16):1511-1520. doi: 10.1056/NEJMcpc2027096. PMID: 34644476; PMCID: PMC8531984.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Richterman A, Bogoch II, Low N, Cevik M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect Dis. 2021 Jun;21(6):e163-e169. doi: 10.1016/S1473-3099(20)30837-9. Epub 2020 Dec 7. PMID: 33301725; PMCID: PMC7834404.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><span style="font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;"><strong>Meyerowitz EA</strong>, Sen P, Schoenfeld SR, Neilan TG, Frigault MJ, Stone JH, Kim AY, Mansour MK. Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. Clin Infect Dis. 2021 Jun 15;72(12):e1130-e1143. doi: 10.1093/cid/ciaa1759. PMID: 33216852; PMCID: PMC7717185.</span></span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;">Richterman A, <strong>Meyerowitz EA</strong>, Cevik M. Hospital-Acquired SARS-CoV-2 Infection: Lessons for Public Health. JAMA. 2020 Nov 13. doi: 10.1001/jama.2020.21399. Epub ahead of print. PMID: 33185657.</span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><strong>Meyerowitz EA</strong>, Sanchez S, Mansour MK, Triant VA , Goldberg MB, Isolated Cerebral Mucormycosis in Immunocompetent Adults Who Inject Drugs: Case Reports and Systematic Review of the Literature, Open Forum Infectious Diseases, , ofaa552, https://doi.org/10.1093/ofid/ofaa552</span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;">Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, <strong>Meyerowitz E</strong>, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Oct 21:NEJMoa2028836. doi: 10.1056/NEJMoa2028836. Epub ahead of print. PMID: 33085857; PMCID: PMC7646626.</span></span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Meyerowitz EA</strong>, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2020 Sep 17:M20-5008. doi: 10.7326/M20-5008. Epub ahead of print. PMID: 32941052; PMCID: PMC7505025.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Meyerowitz EA</strong>, Kim AY, Ard KL, Basgoz N, Chu JT, Hurtado RM, Lee CK, He W, Minukas T, Nelson S, Ojikutu BO, Robbins G, Sanchez S, Triant VA, Zachary K, Gandhi RT. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. AIDS. 2020 Oct 1;34(12):1781-1787. doi: 10.1097/QAD.0000000000002607. PMID: 32604138; PMCID: PMC7499878.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Meyerowitz EA</strong>, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J. 2020 May;34(5):6027-6037. doi: 10.1096/fj.202000919. Epub 2020 Apr 29. PMID: 32350928; PMCID: PMC7267640.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Bloom PP, <strong>Meyerowitz EA</strong>, Reinus Z, Daidone M, Gustafson J, Kim AY, Schaefer E, Chung RT. Liver Biochemistries in Hospitalized Patients With COVID-19. Hepatology. 2020 May 16. doi: 10.1002/hep.31326. Epub ahead of print. PMID: 32415860.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">McCarthy CP, Murphy S, Jones-O'Connor M, Olshan DS, Khambhati JR, Rehman S, Cadigan JB, Cui J, <strong>Meyerowitz EA</strong>, Philippides G, Friedman LS, Kadar AY, Hibbert K, Natarajan P, Massaro AF, Bohula EA, Morrow DA, Woolley AE, Januzzi JL Jr, Wasfy JH. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020 Sep;26:100504. doi: 10.1016/j.eclinm.2020.100504. Epub 2020 Aug 19. PMID: 32838244; PMCID: PMC7434634.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Gong J, <strong>Meyerowitz EA</strong>, Isidro RA, Kaye KM. Primary cytomegalovirus infection with invasive disease in a patient with inflammatory bowel disease. BMJ Case Rep. 2019 Sep 30;12(9):e230056. doi: 10.1136/bcr-2019-230056. PMID: 31570344; PMCID: PMC6768388.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;"><strong>Meyerowitz EA</strong>, Prager S, Stout K, Roxby A. Endocarditis following IUD insertion in a patient with tetralogy of Fallot. BMJ Case Rep. 2019 Feb 7;12(2):e227962. doi: 10.1136/bcr-2018-227962. PMID: 30737328; PMCID: PMC6381954.</span></p>
<p><span style="color: #212121; font-family: system-ui, -apple-system, Segoe UI, Roboto, Oxygen, Ubuntu, Cantarell, Fira Sans, Droid Sans, Helvetica Neue, sans-serif;"><span style="font-size: 16px;"><strong>Meyerowitz, E</strong>. and S. Dhanireddy. “Care of the Elderly Patient with Infective Endocarditis.” Current Geriatrics Reports 6 (2017): 290-296.</span></span></p>
<p>Eric A. Meyerowitz, MD, is an attending physician at Montefiore Einstein and Assistant Professor, Medicine at our Albert Einstein College of Medicine. Dr. Meyerowitz’s clinical focus centers on the care of people with a broad range of infectious diseases, including those living with HIV, HTLV-1 and other chronic viral infections, as well as those with chronic mycobacterial infections. He also specializes in the treatment and prevention of sexually transmitted infections and cares for many patients on pre-exposure prophylaxis (PrEP) and Doxycycline Post-Exposure Prophylaxis (doxy-PEP).</p><p>After obtaining his Bachelor of Arts in chemistry from Harvard College in 2010, Dr. Meyerowitz earned his Doctor of Medicine at the Perelman School of Medicine at the University of Pennsylvania in 2015. He completed an internship in internal medicine at the University of Washington in 2016, followed by an internal medicine residency in the HIV pathway at the same institution in 2018. Following this, Dr. Meyerowitz completed a fellowship in infectious diseases in the HIV clinician/educator pathway at Massachusetts General Hospital in 2020.</p><p>Dr. Meyerowitz’s research focuses on HIV treatment and prevention strategies, treatments for people with HTLV-1 associated myelopathy (also called tropical spastic paraparesis), implementation of STI prevention strategies and treatment trials for non-tuberculous mycobacterial infections. His work has been published in numerous peer-reviewed journals and shared through abstracts, poster presentations, invited presentations and review articles.</p><p>Dr. Meyerowitz is board certified in Internal Medicine and Infectious Diseases. He is a member of the Infectious Diseases Society of America. In 2022, Dr. Meyerowitz received the Infectious Diseases Fellow Teaching Award from Montefiore Einstein.</p>
<p>I'm currently the chairman of the Institutional Review Board at Einstein and Montefiore, co-chairman of the Institutional Review Board of the Biomedical Research Alliance of New York, and chairman of the Pharmacy and Therapeutics Committee for the Montefiore Health System.</p>
<p>After being the fellowship program director for the Division of Infectious Diseases for 12 years, I've stepped back but continue serve as assistant program director. I'm also responsible for the content of the division's web pages on the Montefiore Intranet.</p>
<p>Please contact me via e-mail for any questions or comments concerning these areas.</p>
<p> </p>
<p>Marla Keller, MD is a tenured Professor of Medicine, Obstetrics & Gynecology and Women’s Health, named holder of the Jacob and Jeanne Barkey Chair in Medicine, and Executive Dean. She previously served as Interim Senior Associate Dean for Clinical and Translational Research, Director of the Harold and Muriel Block Institute for Clinical and Translational Research, and Vice Chair of Research for the Department of Medicine.</p>
<p>Dr. Keller received a Bachelor of Arts degree in psychology from Cornell University and a medical degree from New York University School of Medicine. She completed residency training in Internal Medicine at Beth Israel Hospital and fellowship in the combined Infectious Diseases training program at Beth Israel Hospital and Brigham & Women's Hospital in Boston, MA. She completed the Clinical Research Training Program at Mount Sinai School of Medicine and was on the faculty at Mount Sinai for 9 years before arriving at Einstein and Montefiore in 2007.<span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"> </span></p>
<p>She is a practicing Infectious Diseases physician with a clinical and research interest in the prevention and treatment of human immunodeficiency virus (HIV) and herpes simplex virus (HSV) infection in adult and adolescent women. Her NIH-funded research includes the design and conduct of human studies to translate laboratory and animal findings to the clinic with the goal of developing novel preventive strategies to reduce the global burden of HIV and HSV. Her interest is in advancing development of topical pre-exposure prophylaxis (PrEP) strategies to reduce the sexual transmisssion of HIV and HSV-2. She has completed first-in-human and Phase 1 safety, pharmacokinetic (PK) and pharmacodynamic (PD) trials of novel vaginal microbicide candidates and formulations (gels, tablets, and rings) for PrEP and contraception. She has also led clinical studies to examine effects of HIV, HSV and bacterial vaginosis on female genital tract immunity and the vaginal microbiome. </p>
<p>Dr. Keller is a co-investigator of the Bronx Clinical Research Site of the NIH-funded Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS) Combined Cohort Study (CCS). Her work with MACS/WIHS-CCS focuses on improving cervical cancer screening practices in women living with HIV infection.</p>
<p>Dr. Keller led the COVID-19 Treatment Taskforce for the Department of Medicine to provide guidance on therapeutic management of patients with COVID-19. She was a co-investigator on COVID-19 therapeutic trials and studies to understand immune responses to SARS-CoV-2 infection in adult and pediatric patients. She served as a scientific member of the NIH COVID-19 Treatment Guidelines Panel from 2020-2024. </p>
<p>Dr. Keller is a member and fellow of the Infectious Disease Society of America (IDSA), a member of the Infectious Diseases Society of New York (IDSNY), and a member of the HIV Medical Association (HIVMA). She served for 9 years as a scientific member of the U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents Living with HIV. </p>
Dr. Keller's clinical focus centers on treating HIV and COVID-19 and offering in-patient infectious disease consultation.
Prevention and treatment of HIV infection in women, advancing the development of vaginal drugs and new strategies to prevent HIV and other sexually transmitted infections, immune responses to SARS-CoV-2 infection and COVID-19 clinical trials.
<p style="text-align: left;">Keller MJ, Mesquita PMM, Torres M, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 5:e8781, 2010.</p>
<p style="text-align: left;">Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PMM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CH, Herold BC. A randomized trial to assess anti-HIV activity in female genital tract secretions & soluble mucosal immunity following application of 1% tenofovir gel. PLoS One, 6:e16475, 2011.</p>
<p style="text-align: left;">Herold BC, Mesquita PMM, Madan Rp, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. American Journal of Reproductive Immunology, 65:325-333, 2011.</p>
<p style="text-align: left;">Keller MJ, Malone AM, Carpenter CA, Lo Y, Huang M, Corey L, Willis R, Nguyen C, Kennedy S, Gunawardana M, Guerrero D, Moss JA, Baum MM, Smith TJ, Herold BC. Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. Journal of Antimicrobial Chemotherapy, 67:2005-12, 2012.</p>
<p style="text-align: left;">Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts DH, Levine AM, Castle PE, Colie C, Palefsky JM, Strickler HD. Risk of cervical precancer and cancer among HIV-infected women with normal cytology and no evidence of oncogenic HPV infection. JAMA, 308:362-369, 2012. </p>
<p style="text-align: left;">Keller MJ, Madan RP, Shust G, Torres NM, Cho S, Khine H, Huang M, Corey L, Kim M, Herold BC. Changes in the soluble mucosal immune environment during genital herpes outbreaks. Journal of Acquired Immune Deficiency Syndromes, 61:194-202, 2012.</p>
<p style="text-align: left;">Keller MJ, Carpenter CA, Lo Y, Einstein MH, Lu C, Fredricks DN, Herold BC. Phase I randomized safety study of twice daily dosing of Acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One, 7:e46901, 2012.</p>
<p style="text-align: left;">Keller MJ, Buckley N, Katzen LL, Walsh J, Friedland B, Littlefield S, Lin J, Xue X, Cornelison T, Herold BC, Einstein MH. Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sexually Transmitted Diseases, 40:939-943, 2013 </p>
<p style="text-align: left;">Herold BC, Keller MJ, Shi Q, Hoover DR, Carpenter CA, Parikh UM, Agnew KJ, Minkoff H, Colie C, Nowicki MJ, D’Souza G, Anastos K. Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes, 63:485-493, 2013.</p>
<p style="text-align: left;">Ursell LK, Gunawardana M, Chang S, Mullen M, Moss JA, Herold BC, Keller MJ, McDonald D, Gonzalez A, Knight R, Baum MM. Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings. Antiviral Research, 102:87-94, 2014.</p>
<p style="text-align: left;">Dominguez-Villar M, Gautron A, de Marcken M, Keller MJ, Hafler DA. TLR7 induces anergy in human CD4(+) T cells. Nature Immunology, 16:118-128, 2015. </p>
<p style="text-align: left;">Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Castle PE, Anastos A, Xie X, Minkoff H, Xue X, D’Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Fischl MA, Palefsky JM, Strickler HD. Cervical precancer risk in HIV-infected women who test positive for oncogenic human papillomavirus despite a normal Pap test. Clin Infect Dis, 61:1573-1581, 2015. </p>
<p style="text-align: left;">Nakra NA, Madan RP, Buckley N, Huber AM, Freiemuth J, Espinoza L, Walsh J, Parikh UM, Penrose KJ, Keller MJ, Herold BC. Loss of innate host defense following unprotected vaginal sex. Journal of Infectious Diseases, 213:840-847, 2016. </p>
<p style="text-align: left;">Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS, 30:743-751, 2016. </p>
<p style="text-align: left;">Keller MJ, McGinn AP, Lo Y, Huber A, Espinoza L, Minkoff H, Colie C, Nowicki MJ, D’Souza G, Anastos K. Longitudinal assessment of systemic and genital tract inflammatory markers and endogenous genital tract <em>E. coli</em> inhibitory activity in HIV-infected and uninfected women. American Journal of Reproductive Immunology, 75:631-42, 2016.</p>
<p style="text-align: left;">Novetsky AP, Keller MJ, Gradissimo A, Chen Z, Morgan SL, Xue X, Strickler HD, Fernandez-Romero JA, Burk R, Einstein MH. In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel. Gynecologic Oncology, 143:313-18, 2016.</p>
<p style="text-align: left;">Massad LS, Keller MJ, Xie X, Minkoff H, Palefsky J, D’Souza G, Colie C, Villacres MC, Strickler HD. Multitype infections with human papillomavirus: impact of HIV coinfection. Sexually Transmitted Diseases, 43:637-641, 2016.</p>
<p style="text-align: left;">Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H, Keller MJ, Fischl M, Burk RD, Palefsky J, Flowers L, Rahangdale L, Milam J, Shrestha S, Colie C, D’Souza G. Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach. AIDS, 31:1035-1044, 2017.</p>
<p style="text-align: left;">Mesquita PM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC. Role of IL-32 in HIV reactivation and its link to HIV-HSV coinfection. Journal of Infectious Diseases, 215:614-622, 2017.</p>
<p style="text-align: left;">Watnick D, Keller MJ, Stein K, Bauman LJ. Acceptability of a tenofovir disoproxil fumarate vaginal ring for HIV prevention among women in New York City. AIDS and Behavior, 22:421-436, 2018.</p>
<p style="text-align: left;">Taneva E, Sinclair S, Mesquita PMM, Weinrick B, Cameron SA, Cheshenko N, Reagle K, Frank B, Keller MJ, Srinivasan S, Fredricks D, Herold BC. Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. JCI Insight 3(13):e99545, 2018.</p>
<p style="text-align: left;">Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Anastos K, Xie X, Minkoff H, Xue X, Reimers LL, Kuniholm M, D’Souza G, Colie C, Palefsky JM, Strickler HD. Racial differences in HPV types among US women with HIV and cervical precancer. AIDS, 32:2821-2826, 2018.</p>
<p style="text-align: left;">Murphy K, Keller MJ, Anastos K, Sinclair S, Devlin JC, Shi Q, Hoover DR, Starkman B, McGillick J, Mullis C, Minkoff H, Dominguez-Bello MG, Herold BC. Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection. PLoS One, 14:e0216049, 2019.</p>
<p style="text-align: left;"><!--[endif]-->Keller MJ, Huber A, Espinoza L, Serrano MG, Parikh HI, Buck GA, Gold JA, Wu Y, Wang T, Herold BC. Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome. Journal of Infectious Diseases, 220:852-861, 2019.</p>
<p style="text-align: left;">Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke M, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo NR, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomized, controlled trial. Lancet HIV, 6:e498-e508, 2019.</p>
<p style="text-align: left;">Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, Tomer Y, Southern W. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. Journal of Hospital Medicine, 15:489-493, 2020.</p>
<p style="text-align: left;">Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ, Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A, Keller MJ, Herold KC, Herold BC. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine, 12(564): eabd5487, 2020.</p>
<p style="text-align: left;">Strickler HD, Keller MJ, Hessol NA, Eltoum IE, Einstein MH, Castle PE, Massad LS, Flowers L, Rahangdale L, Atrio JM, Ramirez C, Minkoff H, Adimora AA, Ofotokun I, Colie C, Huchko MJ, Fischl M, Wright R, D’Souza G, Leider J, Diaz O, Sanchez-Keeland L, Shrestha S, Xie X, Xue X, Anastos K, Palefsky JM, Burk RD. Primary HPV and molecular cervical cancer screening in US women living with HIV. Clinical Infectious Diseases, 72:1529-1537, 2021.</p>
<p style="text-align: left;">Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, Glidden DV, Grund B, Gulick RM, Harrison C, Kim A, Lane HC, Masur H, Sheikh V, Singh K, Yazdany J, Tebas P. Convalescent plasma for the treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Annals of Internal Medicine, 174(1):93-95, 2021.</p>
<p style="text-align: left;"><!-- [if !supportLists]-->Tomer Y, Gong MN, Keller MJ, Southern W, Kitsis EA, Kajita GR, Shapiro LI, Jariwala S, Epstein EJ. Teamwork and leadership under fire at the epicenter of the COVID-19 epidemic in the Bronx. Frontiers in Medicine, 8:610100, 2021.</p>
<p style="text-align: left;">Pierce CA, Sy S, Galen B, Goldstein DY, Orner E, Keller MJ, Herold KC, Herold BC. Natural mucosal barriers and COVID-19 in children. JCI Insight, 6(9):e148694, 2021.</p>
<p style="text-align: left;">Serebrenik JS, Wang T, Hunte R, Srinivasan S, McWalters J, Tharp GK, Bosinger SE, Fiedler TL, Atrio JM, Murphy K, Barnett R, Ray LR, Krows ML, Fredricks DN, Irungu E, Ngure K, Mugo N, Marrazzo J, Keller MJ, Herold BC. Differences in vaginal microbiota, host transcriptome and proteins in women with bacterial vaginosis are associated with metronidazole response. Journal of Infectious Diseases 224(12):2094-2104, 2021.</p>
<p style="text-align: left;">Kim M, Marantz P, Suadicani S, Milman S, Keller MJ. Challenges in catalyzing and sustaining research in translational science. Journal of Clinical and Translational Science 7;e217, 1-5, 2023.</p>
<p style="text-align: left;">Murphy K, Gromisch M, Srinivasan S, Wang T, Wood L, Proll S, Liu C, Fiedler T, Valint DJ, Fredricks DN, Keller MJ, Herold BC. IgA coating of vaginal bacteria is reduced in the setting of bacterial vaginosis (BV) and preferentially targets BV-associated bacteria. Infection and Immunity 92(1):e0037323, 2024.</p>
<p style="text-align: justify;"> </p>
<p> </p>
<p> </p>
<p> </p>
<p><!--EndFragment--></p>
<p>Marla Keller, MD is a tenured Professor of Medicine, Obstetrics & Gynecology and Women’s Health, named holder of the Jacob and Jeanne Barkey Chair in Medicine, and Executive Dean. She previously served as Interim Senior Associate Dean for Clinical and Translational Research, Director of the Harold and Muriel Block Institute for Clinical and Translational Research, and Vice Chair of Research for the Department of Medicine. Her clinical focus centers on treating HIV and COVID-19 and offering in-patient infectious disease consultation.</p><p>After earning her Doctor of Medicine at New York University in 1993, Dr. Keller completed her internship and residency in internal medicine at Beth Israel Hospital in 1996. She completed a fellowship in infectious disease in 1998 from the combined training program at Beth Israel Deaconess Medical Center and Brigham and Women’s Hospital. Dr. Keller went on to participate in a Clinical Research Training Program at Mount Sinai School of Medicine, which she completed in 2002. In 2018, Dr. Keller earned a Certification in Leadership Development for Physicians in Academic Health Centers from Harvard University.</p><p>Building on her clinical focus, Dr. Keller’s research interests include the prevention and treatment of HIV infection in women, advancing the development of vaginal drugs and new strategies to prevent HIV and other sexually transmitted infections, immune responses to SARS-CoV-2 infection and COVID-19 clinical trials. She has been Principal Investigator or Co-Investigator on many NIH-funded research projects and clinical trials, and she has given national and international presentations. Her work has been published in numerous peer-reviewed journals.</p><p>Dr. Keller is board certified in Infectious Diseases by the American Board of Internal Medicine. She is a member of several professional organizations, including the Infectious Disease Society of America, the HIV Medicine Association and the Infectious Disease Society of New York. Dr. Keller has won several awards for her work, including the Infectious Disease Mentoring Award from Montefiore in 2013, the COVID-19 Distinguished Service Award from the Department of Medicine in 2021 and the Spirit of Achievement Changemaker Award from Einstein in 2023. She was also named a New York Super Doctor from 2011 to 2015.</p>
<p>Clinical studies of HIV infection, adherence, and tuberculosis</p>
Management of HIV infection
New antiretroviral medication and new strategies to treat HIV.
<p>Robert Grossberg, MD, is Medical Director, Center for Positive Living/Infectious Diseases Clinic and Professor, Medicine at Montefiore-Einstein. His clinical focus is on the management of HIV infection. He has over 20 years of experience in treating patients with HIV. Dr. Grossberg also sees patients with general infectious disease conditions.</p><p>After obtaining his undergraduate degree at Brown University in 1992, Dr. Grossberg earned his Doctor of Medicine at Brown University School of Medicine in 1996. He completed an internal medicine internship and residency at the Hospital of the University of Pennsylvania in 1999. Dr. Grossberg remained at this institution to complete an infectious diseases fellowship in 2001.</p><p>Dr. Grossberg has extensive experience in clinical trials, particularly trials of new antiretroviral medication and new strategies to treat HIV. He has been the principal investigator (PI) of numerous industry-sponsored studies and collaborated with investigators throughout the country and internationally. Dr. Grossberg was also the PI at Montefiore for several pivotal studies investigating treatments for COVID-19. His work has been published in numerous peer-reviewed journals, books, chapters, articles and abstracts, and he has given invited presentations nationally. Dr. Grossberg has been a reviewer for scientific journals including <em>AIDS and Behavior, Clinical Infectious Diseases</em> and the <em>European Journal of Clinical Microbiology and Infectious Diseases</em>.</p><p>Dr. Grossberg is board certified in Internal Medicine and Infectious Diseases. He is a member of the Infectious Diseases Society of America, the HIV Medicine Association and the Infectious Diseases Society of New York. Dr. Grossberg has been named in Castle Connolly’s “Top Doctors: New York Metro Area” for several years and in <em>New York Magazine’s</em> Top Doctors in 2021.</p>
<p>Our primary research interest is in the biology, pathogenesis and immunology of <em>Plasmodium falciparum.</em> Patients infected with this parasite can be completely asymptomatic or develop severe disease resulting in death. The goal of our research has been to define the molecular mechanisms that underlie this variation in disease outcomes in <em>P. falciparum.</em> Toward this goal, we have developed a new pathogenesis model through the analysis of <em>in vivo</em> parasite biology and associated host factors using a whole genome and metabolomic approach. We have identified novel parasite biology when it resides in the human host and idnetified a putative mediator of coma in cerebral malaria. We also are studying adjunctive therapy to improve outcomes in severe malaria using the animal model. We carry out field based translational studies in cohorts infected with malaria in Africa and test hypothesis in the animal model of malaria. The long term goal is to identify parasite and host processes involved in disease to serve as targets for vaccine or chemotherapeutic development.</p>
<p>Our group also conducts studies to characterize the effect of COVID-19 on brain function in collaboration with Dr. Michael Liptons group and identifying patients with other emerging viral infections in collaboration with Drs Chandran and Lai's group.</p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Keswani T, Obeidallah A, Nieves E, Sidoli S, Fazzari M, Taylor T, Seydel K, Daily JP. <strong>Pipecolic Acid, a Putative Mediator of the Encephalopathy of Cerebral Malaria and the Experimental Model of Cerebral Malaria.</strong> J Infect Dis. 2022 Feb 15;225(4):705-714. doi: 10.1093/infdis/jiab615. PMID: 34932816; PMCID: PMC8844588.</span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Mita-Mendoza NK, Magallon-Tejada A, Parmar P, Furtado R, Aldrich M, Saidi A, Taylor T, Smith J, Seydel K, Daily JP. <strong>Dimethyl fumarate reduces TNF and Plasmodium falciparum induced brain endothelium activation in vitro</strong>. Malar J. 2020 Oct 21;19(1):376. doi: 10.1186/s12936-020-03447-7. PMID: 33087130; PMCID: PMC7579885.</span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Chen V, Daily JP. <strong>Tafenoquine: the new kid on the block</strong>. Curr Opin Infect Dis. 2019 Oct;32(5):407-412. doi: 10.1097/QCO.0000000000000574. PMID: 31305490.</span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Lasso G, Khan S, Allen SA, Mariano M, Florez C, Orner EP, Quiroz JA, Quevedo G, Massimi A, Hegde A, Wirchnianski AS, Bortz RH 3rd, Malonis RJ, Georgiev GI, Tong K, Herrera NG, Morano NC, Garforth SJ, Malaviya A, Khokhar A, Laudermilch E, Dieterle ME, Fels JM, Haslwanter D, Jangra RK, Barnhill J, Almo SC, Chandran K, Lai JR, Kelly L, Daily JP, Vergnolle O. <strong>Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes.</strong> PLoS Comput Biol. 2022 Jan 18;18(1):e1009778. doi: 10.1371/journal.pcbi.1009778. PMID: 35041647; PMCID: PMC8812869.</span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE.<strong> Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.</strong> JAMA Intern Med. 2022 Feb 1;182(2):115-126. doi: 10.1001/jamainternmed.2021.6850. PMID: 34901997; PMCID: PMC8669605.</span></p>
<p><span style="color: #212121; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">Ahmed A, Daily JP, Lescano AG, Golightly LM, Fasina A.<strong> Challenges and Strategies for Biomedical Researchers Returning to Low- and Middle-Income Countries after Training</strong>. Am J Trop Med Hyg. 2020 Mar;102(3):494-496. doi: 10.4269/ajtmh.19-0674. PMID: 31912776; PMCID: PMC7056415.</span></p>
<p> </p>
<p> </p>